Hitchhiking to brain tumours: stem cell delivery of oncolytic viruses
Mené entre 2017 et 2019 sur 12 patients atteints d'un gliome de haut grade récemment diagnostiqué (durée médiane de suivi : 18 mois), cet essai de phase I évalue la dose maximale tolérée et la toxicité de NSC-CRAd-S-pk7, un adénovirus oncolytique modifié injecté dans les parois de la cavité de résection
Three studies have reported the results of phase 1 clinical trials of virotherapy for malignant gliomas, underscoring the momentum in the field. In the first study, investigators used a replication-competent, tumour-selective adenovirus to treat patients with recurrent glioblastomas. In a group in which patients received virus treatment only (n=25), 20% of the patients survived more than 3 years after treatment, and three patients had tumour volume reductions of 95% or more. In the second study, intratumoural infusion of a tumour-selective poliovirus into patients with recurrent malignant glioma improved overall survival, which reached a plateau of 21% at 24 months that was sustained at 36 months. In the most recent report, investigators treated children with malignant gliomas with intratumoural injections of a herpes simplex virus. The median overall survival time was 12·2 months (8·0–16·4), and four (36%) of 11 patients were still alive 18 months after virotherapy. These trials support the concept of oncolytic virotherapy as a unique approach for cancer immunotherapy.
The Lancet Oncology , commentaire en libre accès, 2021